Cargando…
Rare upper gastrointestinal hemorrhage of cetuximab: A case report
RATIONALE: cetuximab, an epidermal growth factor receptor inhibitor, is a targeted therapeutic regimen of colorectal cancers. Several common adverse effects have been found, such as cutaneous or gastrointestinal toxicity. However, according to the articles had been published, upper gastrointestinal...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758247/ https://www.ncbi.nlm.nih.gov/pubmed/29390545 http://dx.doi.org/10.1097/MD.0000000000009391 |
_version_ | 1783290974195154944 |
---|---|
author | Duan, Shi-Jie Gao, Zi-Ming Wang, Peng-Liang Gong, Bao-Cheng Huang, Han-Wei Luo, Lei Wang, Xin Xing, Ya-Nan Xu, Hui-Mian Liu, Fu-Nan |
author_facet | Duan, Shi-Jie Gao, Zi-Ming Wang, Peng-Liang Gong, Bao-Cheng Huang, Han-Wei Luo, Lei Wang, Xin Xing, Ya-Nan Xu, Hui-Mian Liu, Fu-Nan |
author_sort | Duan, Shi-Jie |
collection | PubMed |
description | RATIONALE: cetuximab, an epidermal growth factor receptor inhibitor, is a targeted therapeutic regimen of colorectal cancers. Several common adverse effects have been found, such as cutaneous or gastrointestinal toxicity. However, according to the articles had been published, upper gastrointestinal bleeding (UGIB) is considered to be rare and its mechanism remains unclear. PATIENT CONCERNS: In this report, we presented a 42-year-old male patient with advanced recto-sigmoid cancer. After palliative operation, the patient suffered from complete upper gastrointestinal (GI) obstruction, which was induced by extensive abdominal metastasis of the tumor. Considering his poor condition, we chose the targeted drug, cetuximab, as his further treatment. But after the application of cetuximab, the UGIB immediately happened twice in this patient. DIAGNOSIS: UGIB, as a rare complication of cetuximab, occured to the patient. INTERVENTIONS: We stopped the bleeding with thrombin, hemocoagulase and somatostatin and suspended the subsequent treatment plan of cetuximab. At the same time, anti-shock treatment was given immediately. OUTCOMES: He was died of respiratory and circulatory failure caused by UGIB and advanced tumor eventually. LESSONS: UGIB should be considered as a rare but severe complication of cetuximab. When cetuximab is applied for patients with advanced colon tumors, more cautions should be required if the patients are accompanied by upper gastrointestinal obstruction. In addition, for those patients who suffered from UGIB recently, cetuximab should be prohibited if the Rockall score ranged > 5 points. |
format | Online Article Text |
id | pubmed-5758247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-57582472018-01-29 Rare upper gastrointestinal hemorrhage of cetuximab: A case report Duan, Shi-Jie Gao, Zi-Ming Wang, Peng-Liang Gong, Bao-Cheng Huang, Han-Wei Luo, Lei Wang, Xin Xing, Ya-Nan Xu, Hui-Mian Liu, Fu-Nan Medicine (Baltimore) 5700 RATIONALE: cetuximab, an epidermal growth factor receptor inhibitor, is a targeted therapeutic regimen of colorectal cancers. Several common adverse effects have been found, such as cutaneous or gastrointestinal toxicity. However, according to the articles had been published, upper gastrointestinal bleeding (UGIB) is considered to be rare and its mechanism remains unclear. PATIENT CONCERNS: In this report, we presented a 42-year-old male patient with advanced recto-sigmoid cancer. After palliative operation, the patient suffered from complete upper gastrointestinal (GI) obstruction, which was induced by extensive abdominal metastasis of the tumor. Considering his poor condition, we chose the targeted drug, cetuximab, as his further treatment. But after the application of cetuximab, the UGIB immediately happened twice in this patient. DIAGNOSIS: UGIB, as a rare complication of cetuximab, occured to the patient. INTERVENTIONS: We stopped the bleeding with thrombin, hemocoagulase and somatostatin and suspended the subsequent treatment plan of cetuximab. At the same time, anti-shock treatment was given immediately. OUTCOMES: He was died of respiratory and circulatory failure caused by UGIB and advanced tumor eventually. LESSONS: UGIB should be considered as a rare but severe complication of cetuximab. When cetuximab is applied for patients with advanced colon tumors, more cautions should be required if the patients are accompanied by upper gastrointestinal obstruction. In addition, for those patients who suffered from UGIB recently, cetuximab should be prohibited if the Rockall score ranged > 5 points. Wolters Kluwer Health 2017-12-22 /pmc/articles/PMC5758247/ /pubmed/29390545 http://dx.doi.org/10.1097/MD.0000000000009391 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Duan, Shi-Jie Gao, Zi-Ming Wang, Peng-Liang Gong, Bao-Cheng Huang, Han-Wei Luo, Lei Wang, Xin Xing, Ya-Nan Xu, Hui-Mian Liu, Fu-Nan Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
title | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
title_full | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
title_fullStr | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
title_full_unstemmed | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
title_short | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
title_sort | rare upper gastrointestinal hemorrhage of cetuximab: a case report |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758247/ https://www.ncbi.nlm.nih.gov/pubmed/29390545 http://dx.doi.org/10.1097/MD.0000000000009391 |
work_keys_str_mv | AT duanshijie rareuppergastrointestinalhemorrhageofcetuximabacasereport AT gaoziming rareuppergastrointestinalhemorrhageofcetuximabacasereport AT wangpengliang rareuppergastrointestinalhemorrhageofcetuximabacasereport AT gongbaocheng rareuppergastrointestinalhemorrhageofcetuximabacasereport AT huanghanwei rareuppergastrointestinalhemorrhageofcetuximabacasereport AT luolei rareuppergastrointestinalhemorrhageofcetuximabacasereport AT wangxin rareuppergastrointestinalhemorrhageofcetuximabacasereport AT xingyanan rareuppergastrointestinalhemorrhageofcetuximabacasereport AT xuhuimian rareuppergastrointestinalhemorrhageofcetuximabacasereport AT liufunan rareuppergastrointestinalhemorrhageofcetuximabacasereport |